Supporting this, the combination of capivasertib (AKT inhibitor) and dasatinib (Src inhibitor) synergistically suppressed cancer cell proliferation in PTEN-deficient models, including patient-derived xenograft (PDX) systems. Here, AKT1 is linked to cancer.